Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Selective Extended Venous Stripping Versus Standard Microsurgical Varicocelectomy for Varicocele-Related Male Infertility

NCT07605351 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-15
Last updated
2026-05-22

Condition(s) studied

VaricoceleMale Infertility

Investigational drug(s) / intervention(s)

Microsurgical Subinguinal Varicocelectomy With Selective Extended Venous StrippingStandard Microsurgical Subinguinal Varicocelectomy With Conventional Vein Ligation

Microsurgical Subinguinal Varicocelectomy With Selective Extended Venous Stripping: Microsurgical subinguinal varicocelectomy performed under magnification with preservation of the testicular artery, lymphatic channels, vas deferens, and vasal vessels. Favorable clinically relevant dilated veins will be dissected, mobilized, stripped over a defined segment, ligated, and divided. Veins not suitable for safe stripping will be treated by standard ligation and division.

Standard Microsurgical Subinguinal Varicocelectomy With Conventional Vein Ligation: Standard microsurgical subinguinal varicocelectomy performed under magnification. Identified veins requiring treatment will be isolated, ligated, and divided while preserving the testicular artery, lymphatic channels, vas deferens, and vasal vessels. Venous stripping will not be performed.

Study summary

Varicocele is a common correctable cause of male infertility and may be associated with abnormal semen parameters, impaired testicular function, and scrotal discomfort. Microsurgical subinguinal varicocelectomy is a commonly used surgical approach because it allows careful preservation of the testicular artery, lymphatic channels, vas deferens, and vasal vessels under magnification. However, persistent or recurrent varicocele may still occur after surgery, possibly because of missed or persistent venous channels.

This randomized controlled trial will compare two surgical techniques in infertile men with clinically palpable varicocele and abnormal semen parameters. Participants will be randomly assigned to either microsurgical subinguinal varicocelectomy with selective extended venous stripping or standard microsurgical subinguinal varicocelectomy with conventional vein ligation and division.

The main purpose of the study is to determine whether selective extended venous stripping reduces the rate of clinically and Doppler-confirmed persistent or recurrent varicocele at 12 months after surgery compared with the standard microsurgical technique. The study will also compare semen parameter improvement, pain improvement in participants with baseline pain, pregnancy outcomes, operative time, postoperative complications, and the need for additional treatment during 12 months of follow-up.

Eligibility

Sex
MALE
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Male patients aged 18 to 50 years. * Couple infertility for at least 12 months. * Clinically palpable grade I to III varicocele confirmed by physical examination. * Abnormal semen parameters documented on at least two semen analyses performed 2 to 4 weeks apart according to World Health Organization laboratory standards. * Female partner evaluation completed or planned, with no untreated severe female factor that would make natural conception impossible. * Willingness to comply with postoperative follow-up at 3, 6, and 12 months. * Written informed consent. Exclusion Criteria: * Azoospermia or cryptozoospermia, defined as absence of sperm in the native ejaculate on at least two baseline semen analyses, including cases in which sperm are detected only after centrifugation. * Known clinically significant chromosomal or genetic abnormality that independently explains severe male infertility, when identified before enrollment. * Previous varicocelectomy of the index side. * Previous inguinal, scrotal, or retroperitoneal surgery that may alter spermatic cord anatomy. * Subclinical varicocele only. * Isolated scrotal pain with normal semen parameters. * Hypogonadotropic hypogonadism requiring hormonal induction therapy. * Testosterone therapy within the previous 6 months. * Use of anti-estrogens, gonadotropins, or aromatase inhibitors within the previous 3 months. * Active genitourinary infection. * Testicular tumor or history of testicular cancer. * Severe systemic disease contraindicating surgery or anesthesia. * Inability to provide informed consent. * Inability or unwillingness to complete follow-up.

Primary outcome measure(s)

  • Persistent or Recurrent Varicocele on the Operated Side — 12 months after surgery
    Persistent or recurrent varicocele will be defined as a palpable varicocele on standing physical examination confirmed by color Doppler ultrasound showing pampiniform plexus vein diameter of at least 3.0 millimeters with reflux lasting more than 2 seconds during Valsalva maneuver. For bilateral surgery, recurrence on either operated side will be counted as recurrence.

Trial sites (1)

FacilityCityRegionStatus
Benha University Hospital Banhā Qalyubia Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07605351 on ClinicalTrials.gov ↗ ← All trials in Egypt